|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Suarez AA, Felix AS and Cohn DE: Bokhman
Redux: Endometrial cancer ‘types’ in the 21st century. Gynecol
Oncol. 144:243–249. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Temkin SM, Minasian L and Noone AM: The
end of the hysterectomy epidemic and endometrial cancer incidence:
What are the unintended consequences of declining hysterectomy
rates? Front Oncol. 6(89)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bendifallah S, Ouldamer L, Lavoue V,
Canlorbe G, Raimond E, Coutant C, Graesslin O, Touboul C, Collinet
P, Daraï E, et al: Groupe de Recherche FRANCOGYN: Patterns of
recurrence and outcomes in surgically treated women with
endometrial cancer according to ESMO-ESGO-ESTRO Consensus
Conference risk groups: Results from the FRANCOGYN study Group.
Gynecol Oncol. 144:107–112. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO Endometrial Consensus Conference Working
Group: ESMO-ESGO-ESTRO consensus conference on endometrial cancer:
Diagnosis, treatment and follow-up. Radiother Oncol. 117:559–581.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Galaal K, Donkers H, Bryant A and Lopes
AD: Laparoscopy versus laparotomy for the management of early stage
endometrial cancer. Cochrane Database Syst Rev.
10(CD006655)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Scaletta G, Dinoi G, Capozzi V, Cianci S,
Pelligra S, Ergasti R, Fagotti A, Scambia G and Fanfani F:
Comparison of minimally invasive surgery with laparotomic approach
in the treatment of high risk endometrial cancer: A systematic
review. Eur J Surg Oncol. 46:782–788. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gueli Alletti S, Cianci S, Perrone E,
Fanfani F, Vascone C, Uccella S, Gallotta V, Vizzielli G, Fagotti
A, Monterossi G, et al: Technological innovation and personalized
surgical treatment for early-stage endometrial cancer patients: A
prospective multicenter Italian experience to evaluate the novel
percutaneous approach. Eur J Obstet Gynecol Reprod Biol.
234:218–222. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gueli Alletti S, Rossitto C, Cianci S and
Scambia G: Telelap ALF-X total hysterectomy for early stage
endometrial cancer: New frontier of robotic gynecological surgery.
Gynecol Oncol. 140:575–576. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Song J, Le T, Hopkins L, Fung-Kee-Fung M,
Lupe K, Gaudet M, E C and Samant R: A comparison of disease
recurrence between robotic versus laparotomy approach in patients
with intermediate-risk endometrial cancer. Int J Gynecol Cancer.
30:160–166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Crosbie E and Morrison J: The emerging
epidemic of endometrial cancer: Time to take action. Cochrane
Database Syst Rev. 12(ED000095)2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Crosbie EJ, Zwahlen M, Kitchener HC, Egger
M and Renehan AG: Body mass index, hormone replacement therapy, and
endometrial cancer risk: A meta-analysis. Cancer Epidemiol
Biomarkers Prev. 19:3119–3130. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
MacKintosh ML and Crosbie EJ: Prevention
strategies in endometrial carcinoma. Curr Oncol Rep.
20(101)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kieszkowski P, Dąbruś D, Grabarek BO and
Boroń D: Differences in the expression pattern of mRNA protein
SEMA3F in endometrial cancer in vitro under cisplatin treatment.
Curr Pharm Biotechnol. 21:1119–1128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Opławski M, Dziobek K, Adwent I, Dąbruś D,
Grabarek B, Zmarzły N, Plewka A and Boroń D: Expression profile of
endoglin in different grades of endometrial cancer. Curr Pharm
Biotechnol. 19:990–995. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Leung YM, Kuo YH, Chao CC, Tsou YH, Chou
CH, Lin CH and Wong KL: Osthol is a use-dependent blocker of
voltage-gated Na+ channels in mouse neuroblastoma N2A
cells. Planta Med. 76:34–40. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wu SN, Lo YK, Chen CC, Li HF and Chiang
HT: Inhibitory effect of the plant-extract osthole on L-type
calcium current in NG108-15 neuronal cells. Biochem Pharmacol.
63:199–206. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
You L, Feng S, An R and Wang X: Osthole: A
promising lead compound for drug discovery from a traditional
Chinese medicine (TCM). Nat Prod Commun. 4:297–302. 2009.PubMed/NCBI
|
|
20
|
Zhang ZR, Leung WN, Cheung HY and Chan CW:
Osthole: A review on its bioactivities, pharmacological properties,
and potential as alternative medicine. Evid Based Complement
Alternat Med. 2015(919616)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Le Zou T, Wang HF, Ren T, Shao ZY, Yuan
RY, Gao Y, Zhang YJ, Wang XA and Liu YB: Osthole inhibits the
progression of human gallbladder cancer cells through JAK/STAT3
signal pathway both in vitro and in vivo. Anticancer Drugs.
30:1022–1030. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jiang G, Liu J, Ren B, Tang Y, Owusu L, Li
M, Zhang J, Liu L and Li W: Anti-tumor effects of osthole on
ovarian cancer cells in vitro. J Ethnopharmacol. 193:368–376.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang J, Zhu XJ, Jin MZ, Cao ZW, Ren YY and
Gu ZW: Osthole induces cell cycle arrest and apoptosis in head and
neck squamous cell carcinoma by suppressing the PI3K/AKT signaling
pathway. Chem Biol Interact. 316(108934)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang B, Zheng X, Liu J, Zhang Z, Qiu C,
Yang L, Zhang L, Zhang Q, Gao H and Wang X: Osthole inhibits
pancreatic cancer progression by directly exerting negative effects
on cancer cells and attenuating tumor-infiltrating M2 macrophages.
J Pharmacol Sci. 137:290–298. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhu X, Li Z, Li T, Long F, Lv Y, Liu L,
Liu X and Zhan Q: Osthole inhibits the PI3K/AKT signaling pathway
via activation of PTEN and induces cell cycle arrest and apoptosis
in esophageal squamous cell carcinoma. Biomed Pharmacother.
102:502–509. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dai X, Yin C, Zhang Y, Guo G, Zhao C, Wang
O, Xiang Y, Zhang X and Liang G: Osthole inhibits triple negative
breast cancer cells by suppressing STAT3. J Exp Clin Cancer Res.
37(322)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Park W, Park S, Song G and Lim W:
Inhibitory effects of osthole on human breast cancer cell
progression via induction of cell cycle arrest, mitochondrial
dysfunction, and ER stress. Nutrients. 11(11)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen J: Multiple signal pathways in
obesity-associated cancer. Obes Rev. 12:1063–1070. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li Y, Zhang Z, Zhang X, Lin Y, Luo T, Xiao
Z and Zhou Q: A dual PI3K/AKT/mTOR signaling inhibitor miR-99a
suppresses endometrial carcinoma. Am J Transl Res. 8:719–731.
2016.PubMed/NCBI
|
|
31
|
Chen J, Zhao KN, Li R, Shao R and Chen C:
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and
mTOR in endometrial cancer. Curr Med Chem. 21:3070–3080.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF,
Yeh JI and Hsu HY: Synergistic anticancer activity of triptolide
combined with cisplatin enhances apoptosis in gastric cancer in
vitro and in vivo. Cancer Lett. 319:203–213. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Arnold M, Rutherford MJ, Bardot A, Ferlay
J, Andersson TM, Myklebust TÅ, Tervonen H, Thursfield V, Ransom D,
Shack L, et al: Progress in cancer survival, mortality, and
incidence in seven high-income countries 1995-2014 (ICBP
SURVMARK-2): A population-based study. Lancet Oncol. 20:1493–1505.
2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fortner RT, Hüsing A, Dossus L, Tjønneland
A, Overvad K, Dahm CC, Arveux P, Fournier A, Kvaskoff M, Schulze
MB, et al: Theoretical potential for endometrial cancer prevention
through primary risk factor modification: Estimates from the EPIC
cohort. Int J Cancer. 147:1325–1333. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Creutzberg CL, van Putten WL, Koper PC,
Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens
LC, van den Bergh AC, van de Steen-Banasik E, et al: Surgery and
postoperative radiotherapy versus surgery alone for patients with
stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC
Study Group. Post operative radiation therapy in endometrial
carcinoma. Lancet. 355:1404–1411. 2000.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Greven K, Winter K, Underhill K,
Fontenesci J, Cooper J and Burke T: Final analysis of RTOG 9708:
Adjuvant postoperative irradiation combined with
cisplatin/paclitaxel chemotherapy following surgery for patients
with high-risk endometrial cancer. Gynecol Oncol. 103:155–159.
2006.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li R, Jiang W, Dou S, Zhong L, Sun J,
Zhang C and Zhu G: A phase II trial of chemoradiotherapy using
weekly docetaxel for high-risk postoperative oral squamous cell
carcinoma patients. Int J Radiat Oncol Biol Phys. 107:462–468.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Susumu N, Sagae S, Udagawa Y, Niwa K,
Kuramoto H, Satoh S and Kudo R: Japanese Gynecologic Oncology
Group. Randomized phase III trial of pelvic radiotherapy versus
cisplatin-based combined chemotherapy in patients with
intermediate- and high-risk endometrial cancer: A Japanese
Gynecologic Oncology Group study. Gynecol Oncol. 108:226–233.
2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lu K, Lin J and Jiang J: Osthole inhibited
cell proliferation and induced cell apoptosis through decreasing
CPEB2 expression via up-regulating miR-424 in endometrial
carcinoma. J Recept Signal Transduct Res. 40:89–96. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326.
1998.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Delbridge AR, Grabow S, Strasser A and
Vaux DL: Thirty years of BCL-2: Translating cell death discoveries
into novel cancer therapies. Nat Rev Cancer. 16:99–109.
2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhang X, Liu X, Zhou D and Zheng G:
Targeting anti-apoptotic BCL-2 family proteins for cancer
treatment. Future Med Chem. 12:563–565. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
LoRusso PM: Inhibition of the
PI3K/AKT/mTOR Pathway in Solid Tumors. J Clin Oncol. 34:3803–3815.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang Y, Kwok-Shing Ng P, Kucherlapati M,
Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R,
Hadjipanayis A, et al: A Pan-cancer proteogenomic atlas of
PI3K/AKT/mTOR pathway alterations. Cancer Cell. 31:820–832.e3.
2017.PubMed/NCBI View Article : Google Scholar
|
